Form 4: Caribou Biosciences CTO Reports Equity Transactions

Caribou Biosciences CTO Timothy P. Kelly reported the acquisition of restricted stock units and stock options, alongside a tax-related sale of common stock.

Summary

• Timothy P. Kelly, Chief Technology Officer of Caribou Biosciences, Inc. (CRBU), reported several equity transactions.
• Acquired 45,000 shares of Common Stock in the form of Restricted Stock Units (RSUs) on February 20, 2026, with a price of $0.
• These RSUs will vest in four equal annual installments beginning on February 20, 2027, contingent on continued service to the Issuer.
• Disposed of 3,147 shares of Common Stock on February 24, 2026, at a price of $1.96 per share.
• This disposition was a mandatory 'sell-to-cover' transaction to satisfy tax withholding obligations related to previously vested RSUs, not a discretionary trade.
• Acquired 202,500 options to purchase Common Stock on February 20, 2026, with an exercise price of $1.8 and an expiration date of February 19, 2036.
• These options will vest monthly, with 1/48th of the total shares vesting on each monthly anniversary of the grant date, fully vesting by February 20, 2030, subject to continued service.
• Following these transactions, Mr. Kelly beneficially owns 79,353 shares of Common Stock directly and 202,500 derivative securities (options) directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively as it indicates significant equity grants to a key executive, fostering alignment with shareholder interests and signaling confidence in long-term value creation, despite a non-discretionary tax-related sale.

Positives

• The grant of 45,000 Restricted Stock Units and 202,500 stock options aligns the Chief Technology Officer's interests with those of shareholders, incentivizing long-term performance and retention.
• The equity grants demonstrate continued commitment to key management personnel.

Risks

• The vesting of both RSUs and stock options is contingent upon the reporting person continuing to provide service to Caribou Biosciences, Inc. through the applicable vesting dates, posing a risk to the full realization of the equity if service is terminated.
• The company's mandatory 'sell-to-cover' policy for tax withholding purposes results in a reduction of direct common stock holdings by insiders, which could be misinterpreted as a discretionary sale.

Future Outlook

The vesting schedules for the granted RSUs and stock options extend through February 2030 and February 2027 respectively, indicating an expectation of continued service from the Chief Technology Officer for several years.

Management Comments

• The disposition of 3,147 shares of common stock reflects the Issuer's mandatory sell-to-cover policy for the sole purpose of satisfying tax withholding obligations in connection with the vesting of previously granted RSUs, and does not represent a discretionary trade by the reporting person.

Industry Context

StockSavvy.ai notes that insider equity grants, such as those reported by Caribou Biosciences' CTO, are common practice across the biotechnology industry to attract, retain, and incentivize key talent. These grants align management's long-term interests with shareholder value creation, a critical factor in a sector characterized by long development cycles and significant R&D investment.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of the Chief Technology Officer's financial interests with long-term shareholder value through significant equity grants.
• Employees (specifically the CTO): Enhanced compensation package and long-term incentive to remain with the company and contribute to its success.

Next Steps

• The 45,000 Restricted Stock Units will begin vesting in four equal annual installments starting February 20, 2027.
• The 202,500 stock options will continue to vest monthly, with full vesting expected by February 20, 2030.
• Settlement of RSUs will occur in stock within 30 days after each vesting date.

Key Dates

Keywords

Caribou Biosciences, CRBU, Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Chief Technology Officer, Timothy P. Kelly, Sell-to-Cover, Beneficial Ownership